Venetoclax CACAG versus 3+7 regimen acute monocytic leukemia

The National Library of Medicine registered a new Phase 2 clinical trial (NCT07512700) on ClinicalTrials.gov investigating venetoclax-based CACAG regimen versus standard 3+7 chemotherapy for acute monocytic leukemia in adult patients. The trial is currently recruiting participants.

Lawyer Niche Focus Builds Expertise, Value Over Price

The American Bar Association published an informational article advising lawyers on practice development strategy. The article argues that lawyers who narrow their practice focus develop deeper expertise, attract higher-value clients, and avoid price competition compared to generalists. The article includes two self-assessment tests for evaluating current positioning.

AI Impact on Law Practice - TECHSHOW 2026 Podcast Recap

The ABA Law Practice Division published a podcast recap from TECHSHOW 2026 featuring three attorneys discussing Jordan Furlong's keynote on AI's impact on legal practice. Panelists addressed AI capabilities resembling a third-year associate, emerging attorney-client privilege questions, debates on bar exam reform and law school relevance, and ethics concerns including hallucinated legal citations. The discussions encouraged lawyers to develop practical AI skills and adopt firm-wide AI policies.

Maria Anzures-Camarena Permanent Debarment - FDA Drug Applications

FDA issued a permanent debarment order for Maria Anzures-Camarena, prohibiting her from submitting or assisting in the preparation of drug applications to the agency. The debarment stems from her felony conviction related to drug application matters. All FDA-regulated drug product applications submitted by or on behalf of Ms. Anzures-Camarena are permanently barred.

Permanent Debarment Order - Miguel Angel Montalvo Villa

The FDA issued a Final Debarment Order permanently excluding Miguel Angel Montalvo Villa from submitting or providing assistance in the preparation of drug applications under section 306(a) or (b) of the FD&C Act. The debarment follows a conviction under federal law related to drug product approval. This action prohibits Montalvo Villa from any role in drug application submissions to FDA.

FDA Permanent Debarment Order - John Warrington Kosolcharoen

FDA issued a final permanent debarment order against John Warrington Kosolcharoen, barring him from participating in any way in the submission of applications for FDA approval or accreditation. The debarment relates to activities concerning FDA-regulated products, specifically applications under the Federal Food, Drug, and Cosmetic Act.

Bernardo Garmendia Permanent Debarment Order

The FDA issued a permanent debarment order against Bernardo Garmendia, preventing him from providing services in any capacity related to drug marketing or distribution under the FD&C Act. The order, effective March 14, 2025, follows Garmendia's felony conviction for a drug-related offense, denying his request for a hearing. Pharmaceutical companies and clinical investigators must ensure no engagement with debarred parties.

Matthew Teltser Permanent Debarment Order

The FDA issued a final order permanently debarring Matthew Teltser from providing services to any person or entity that has an approved or pending drug application. The debarment prohibits Teltser from directly or indirectly participating in any FDA-regulated drug business activities. This enforcement action (Docket No. FDA-2025-N-1956) took effect on February 6, 2026.

Patent Trademark Filing Statistics Overview

The Japan Patent Office released its FY2025 statistical overview covering patent, trademark, utility model, and design filings through Q3. The report provides cumulative data for national applications (363,079 total), international filings via PCT/Hague/Madrid protocols, and patent examination request statistics with year-over-year comparisons. This is routine informational data with no regulatory requirements or compliance obligations.

Patent and Trademark Filing Statistics Overview

The Japan Patent Office released its statistical overview for January 2026, reporting on patent, trademark, and utility model applications. The data covers Q2 and Q3 of FY2025 with cumulative figures, including year-on-year comparisons showing changes in filing volumes. Preliminary data indicates variations in international applications under the Hague Agreement and Madrid Protocol.